**Checklist for Reporting Human Islet Preparations Used in Research**

Adapted from Hart NJ, Powers AC (2018) Progress, challenges, and suggestions for using human islets to understand islet biology and human diabetes. Diabetologia <https://doi.org/10.1007/s00125-018-4772-2>.

|  |  |
| --- | --- |
|  | |
| **Manuscript DOI:** https://doi.org/10.2337/**[DB19-0525.R1]** | |
| **Title: Low Dose IL-2 Combined with Rapamycin Led to an Expansion of CD4+CD25+FOXP3+ Tregs and Prolonged Human Islet-allograft Survival in Humanized Mice** | |
| **Author list:** Min Hu, Wayne J Hawthorne, Leigh Nicholson, Heather Burns, Yi Wen Qian, David Liuwantara, Elvira Jimenez Vera, Yi Vee Chew, Lindy Williams, Shounan Yi, Karen Keung,Debbie Watson, Natasha Rogers, Stephen I Alexander and Philip J O’Connell | |
| **Corresponding author:** Min Hu and Philip J O’Connell | **Email address:min.hu@sydney.edu.au and philip.oconnell@sydney.edu.au** |

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Islet preparation** | **1** | **2** | **3** | **4** | **5** | **6** | **7** | **8a** |
| **MANDATORY INFORMATION** | | | | | | | | |
| Unique identifier | N1572 | W0413 | S0879 | W0452 | N1736 | V1489 | S0908 | Q1157 |
| Donor age (years) | 26 | 24 | 47 | 61 | 51 | 47 | 41 | 56 |
| Donor sex (M/F) | F | M | F | F | F | F | F | M |
| Donor BMI (kg/m2) | 23.39 | 23.55 | 29.76 | 32.69 | 25.39 | 31.14 | 27.77 | 24.15 |
| Donor HbA1c or other measure of blood glucose control | (BSL) 6.1 mmol/L | 8.1 | 11.7 | 9.7 | 7.6 | 6.1 | 6.2 | 6.4 |
| Origin/source of isletsb | Australian Islet Transplant Consortium | Australian Islet Transplant Consortium | Australian Islet Transplant Consortium | Australian Islet Transplant Consortium | Australian Islet Transplant Consortium | Australian Islet Transplant Consortium | Australian Islet Transplant Consortium | Australian Islet Transplant Consortium |
| Islet isolation centre | WIT | WIT | WIT | WIT | WIT | WIT | WIT | WIT |
| Donor history of diabetes? Yes/No | No | No | No | No | No | No | No | No |
| **If Yes, complete the next two lines if this information is available** | | | | | | | | |
| Diabetes duration (years) |  |  |  |  |  |  |  |  |
| Glucose-lowering therapy at time of deathc |  |  |  |  |  |  |  |  |

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **RECOMMENDED INFORMATION** | | | | | | | | |
| Donor cause of death | Intra-operative cerebral haemorrhage | MVA / Cerebral oedema | Cardiac arrest - Hypoxic brain injury | Other spontaneous ICH + Cerebral oedema | ICH | Cerebral Infarct | spontaneous SAH | MVA |
| Warm ischaemia time (h) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cold ischaemia time (h) | 4.33 | 7.33 | 9.25 | 10.67 | 5.37 | 8.37 | 8.42 | 10.15 |
| Estimated purity (%) | 80 | 83 | 85 | 90 | 90 | 95 | 80 | 85 |
| Estimated viability (%) | 84 | 80 | 94 | 94 | 88 | 93 | 98 | 93 |
| Total culture time (h)d | 36 | 56 | 16.5 | 29 | 20 | 12 | 15 | 11.75 |
| Glucose-stimulated insulin secretion or other functional measuremente | 1.03 | 0.82 | 1.39 | 1.45 | 1.31 | 1.82 | 1.47 | 0.64 |
| Handpicked to purity? Yes/No | No | No | No | No | No | No | No | No |
| Additional notes |  |  |  |  |  |  |  |  |

aIf you have used more than eight islet preparations, please complete additional forms as necessary

bFor example, IIDP, ECIT, Alberta IsletCore

cPlease specify the therapy/therapies

dTime of islet culture at the isolation centre, during shipment and at the receiving laboratory

ePlease specify the test and the results